Upgrade to SI Premium - Free Trial

SAB Biotherapeutics (SABS)

3.52 -0.06 (1.68%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/6/26)

Latest Headlines

Form 8-K SAB Biotherapeutics, For: Jul 07 July 7, 2026 8:15 AM - SEC Filing Form 4 SAB Biotherapeutics, For: Jun 25 Filed by: Kropotova Alexandra June 26, 2026 5:20 PM - SEC Filing Barclays Starts SAB Biotherapeutics (SABS) at Overweight June 24, 2026 6:20 AM - StreetInsider Form 8-K SAB Biotherapeutics, For: Jun 18 June 18, 2026 4:35 PM - SEC Filing SAB Biotherapeutics (SABS) PT Raised to $13 at Jefferies June 15, 2026 2:31 PM - StreetInsider Citi Starts SAB Biotherapeutics (SABS) at Buy May 22, 2026 5:08 AM - StreetInsider Jefferies Starts SAB Biotherapeutics (SABS) at Buy May 20, 2026 3:18 AM - StreetInsider Form SCHEDULE 13G/A SAB Biotherapeutics, Filed by: PERCEPTIVE ADVISORS LLC May 15, 2026 4:00 PM - SEC Filing Form SCHEDULE 13G SAB Biotherapeutics, Filed by: Caligan Partners LP May 15, 2026 11:18 AM - SEC Filing Form SCHEDULE 13G SAB Biotherapeutics, Filed by: BALYASNY ASSET MANAGEMENT L.P. May 15, 2026 6:36 AM - SEC Filing SAB Biotherapeutics (SABS) PT Raised to $10 at H.C. Wainwright May 12, 2026 12:07 PM - StreetInsider Form 10-Q SAB Biotherapeutics, For: Mar 31 May 12, 2026 7:36 AM - SEC Filing SAB Biotherapeutics reports Q1 2026 results, enrollment progress May 12, 2026 7:30 AM - StreetInsider SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights May 12, 2026 7:30 AM - Globe NewsWire SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET May 5, 2026 8:30 AM - Globe NewsWire Form 8-K SAB Biotherapeutics, For: Apr 28 May 4, 2026 4:36 PM - SEC Filing Form SCHEDULE 13G SAB Biotherapeutics, Filed by: MILLENNIUM MANAGEMENT LLC May 1, 2026 4:57 PM - SEC Filing Form DEF 14A SAB Biotherapeutics, For: Jun 18 April 30, 2026 4:45 PM - SEC Filing Emergent BioSolutions signs $50 million manufacturing deal with SAB BIO April 29, 2026 7:35 AM - StreetInsider Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142 April 29, 2026 7:35 AM - Globe NewsWire Full Article List